TY - JOUR
T1 - A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation
AU - Fong, Thomas
AU - Trinkaus, Kathryn
AU - Adkins, Douglas
AU - Vij, Ravi
AU - Devine, Steven M.
AU - Tomasson, Michael
AU - Goodnough, Lawrence T.
AU - Lopez, Sandra
AU - Graubert, Timothy
AU - Shenoy, Shalini
AU - DiPersio, John F.
AU - Khoury, Hanna J.
PY - 2007/10
Y1 - 2007/10
N2 - Hydroxychloroquine (HCQ) is an immunosuppressive lysosomotropic amine that has activity against graft-versus-host disease (GVHD). In a single-institution phase III trial, 95 recipients of allogeneic peripheral blood stem cell (PBSC) transplantation were randomized to receive, in a double-blind fashion, and in addition to prophylactic cyclosporine A (CSA), HCQ, or placebo starting 21 days pretransplant and continued until day +365. HCQ was very well tolerated and not associated with side effects. Overall, the incidence of acute GVHD (aGVHD) was 59% in both arms, and severe aGVHD occurred in 11% (HCQ) and 14% (placebo) (P = .76). Sixty percent and 78% of patients developed chronic GVHD (cGVHD) in the HCQ and the placebo arms, respectively (P = .15). With a median follow-up of 18 months, relapse-free and overall survivals (OS) were comparable in both groups. In summary, in this randomized trial, the addition of HCQ to single-agent CSA had no effects on aGVHD or cGVHD or survival.
AB - Hydroxychloroquine (HCQ) is an immunosuppressive lysosomotropic amine that has activity against graft-versus-host disease (GVHD). In a single-institution phase III trial, 95 recipients of allogeneic peripheral blood stem cell (PBSC) transplantation were randomized to receive, in a double-blind fashion, and in addition to prophylactic cyclosporine A (CSA), HCQ, or placebo starting 21 days pretransplant and continued until day +365. HCQ was very well tolerated and not associated with side effects. Overall, the incidence of acute GVHD (aGVHD) was 59% in both arms, and severe aGVHD occurred in 11% (HCQ) and 14% (placebo) (P = .76). Sixty percent and 78% of patients developed chronic GVHD (cGVHD) in the HCQ and the placebo arms, respectively (P = .15). With a median follow-up of 18 months, relapse-free and overall survivals (OS) were comparable in both groups. In summary, in this randomized trial, the addition of HCQ to single-agent CSA had no effects on aGVHD or cGVHD or survival.
KW - Chronic GVHD
KW - Hydroxycholorquine
KW - Propyhlaxis
UR - http://www.scopus.com/inward/record.url?scp=34548701358&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2007.06.012
DO - 10.1016/j.bbmt.2007.06.012
M3 - Article
C2 - 17889357
AN - SCOPUS:34548701358
SN - 1083-8791
VL - 13
SP - 1201
EP - 1206
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 10
ER -